tbuckley/cabot-search huggingface dataset:
Effect of Financial Incentives for Process, Outcomes, or Both on Cholesterol Level Change
Authors: Peter P. Reese, Iwan Barankay, Mary Putt, Louise B. Russell, Jiali Yan, Jingsan Zhu, Qian Huang, George Loewenstein, Rolf Andersen, Heidi Testa, Adam S. Mussell, David Pagnotti, Lisa E. Wesby, Karen Hoffer, Kevin G. Volpp
Journal: JAMA Network Open (2021)

<h3>Importance</h3> Financial incentives may improve health behaviors. It is unknown whether incentives are more effective if they target a key process (eg, medication adherence), an outcome (eg, low-density lipoprotein cholesterol [LDL-C] levels), or both. <h3>Objective</h3> To determine whether financial incentives awarded daily for process (adherence to statins), awarded quarterly for outcomes (personalized LDL-C level targets), or awarded for process plus outcomes induce reductions in LDL-C levels compared with control. <h3>Design, Setting, and Participants</h3> A randomized clinical trial was conducted from February 12, 2015, to October 3, 2018; data analysis was performed from October 4, 2018, to May 27, 2021, at the University of Pennsylvania Health System, Philadelphia. Participants included 764 adults with an active statin prescription, elevated risk of atherosclerotic cardiovascular disease, suboptimal LDL-C level, and evidence of imperfect adherence to statin medication. <h3>Interventions</h3> Interventions lasted 12 months. All participants received a smart pill bottle to measure adherence and underwent LDL-C measurement every 3 months. In the process group, daily financial incentives were awarded for statin adherence. In the outcomes group, participants received incentives for achieving or sustaining at least a quarterly 10-mg/dL LDL-C level reduction. The process plus outcomes group participants were eligible for incentives split between statin adherence and quarterly LDL-C level targets. <h3>Main Outcomes and Measures</h3> Change in LDL-C level from baseline to 12 months, determined using intention-to-treat analysis. <h3>Results</h3> Of the 764 participants, 390 were women (51.2%); mean (SD) age was 62.4 (10.0) years, 310 (40.6%) had diabetes, 298 (39.0%) had hypertension, and mean (SD) baseline LDL-C level was 138.8 (37.6) mg/dL. Mean LDL-C level reductions from baseline to 12 months were −36.9 mg/dL (95% CI, −42.0 to −31.9 mg/dL) among control participants, −40.0 mg/dL (95% CI, −44.7 to −35.4 mg/dL) among process participants, −41.6 mg/dL (95% CI, −46.3 to −37.0 mg/dL) among outcomes participants, and −42.8 mg/dL (95% CI, −47.4 to −38.1 mg/dL) among process plus outcomes participants. In exploratory analysis among participants with diabetes and hypertension, no spillover effects of incentives were detected compared with the control group on hemoglobin A<sub>1c</sub>level and blood pressure over 12 months. <h3>Conclusions and Relevance</h3> In this randomized clinical trial, process-, outcomes-, or process plus outcomes–based financial incentives did not improve LDL-C levels vs control. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT02246959
143P The impact of de-escalation of adjuvant systemic therapy on the outcome of women with early ER+/HER2+ breast cancer
Authors: V. Jerič Horvat, D. Manevski, M. Pohar Perme, B. Gazić, P. Drev, D. Ribnikar, E. Matos, B. Šeruga
Journal: Annals of Oncology (2021)
757P Investigation of PARP inhibitor resistance through the analysis of serially collected circulating tumor DNA (ctDNA) in ovarian cancer patients
Authors: Y-N. Kim, Y. Shim, J-Y. Lee, S-T. Lee, J. Seo, Y.J. Lee, S. Shin, S.W. Kim, J.R. Choi, S. Kim
Journal: Annals of Oncology (2021)
From drug discovery to coronaviruses: why restoring natural habitats is good for human health
Authors: Peninah Murage, Helena Reis Batalha, Silvia Lino, Kamil Sterniczuk
Journal: BMJ (2021)

<b>Peninah Murage and colleagues</b> argue that biodiversity is the cornerstone of healthy natural habitats. Its preservation is vital to human health and should therefore be embedded into medical and healthcare studies
Abstract 12097: Iron Deficiency in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Authors: Giancarlo Marenzi, Nicola Cosentino, Jeness Campodonico, Maria Teresa Cardillo, Gianluca Pontone, Marco Moltrasio, Alice Bonomi, Valentina Milazzo, Mara Rubino, Ivana Marana
Journal: Circulation (2018)

Introduction: Iron deficiency (ID) is an emerging problem and a potential therapeutic target in patients with heart failure. Whether ID is a common co-morbidity also in ST-elevation acute myocardia...
Radical prostatectomy — aftercare should not be an afterthought
Authors: Findlay MacAskill, Arun Sahai, Majed Shabbir, Prokar Dasgupta, Tet Yap, Paul Cathcart, Amy Sandher, Karen Briggs, Christian Brown, Ben Challacombe, Rick Popert, Raveen Sandher, Claire Taylor, Sachin Malde
Journal: Nature Reviews Urology (2021)
301P Integrins in different subsets of circulating tumor cells in breast cancer
Authors: E.S. Grigoryeva, O.E. Savelieva, V.V. Alifanov, L.A. Tashireva, M.V. Zavyalova, N.A. Tarabanovskaya, N.V. Cherdyntseva, V.M. Perelmuter
Journal: Annals of Oncology (2021)
606P Role of serum biomarkers of bone metabolism in metastatic castration-resistance prostate cancer (mCRPC) patients (pts) treated with radium-223 (Ra223): PRORADIUM study final results
Authors: N. Romero Laorden, D. Lorente, R. Lozano Mejorada, N. Sanchez-Soler, G. De Velasco, J. Puente, P. Borrega, E. Gonzalez-Billalabeitia, V. Castillo-Morales, A. Hernández, A. Fernandez-Freire, F. Lopez Campos, R. Villatoro, O. Fernandez Calvo, U. Anido, N. Lainez, R. Luque, S. Ros Martínez, E. Castro, D. Olmos
Journal: Annals of Oncology (2021)
Endoscopic internal drainage using double-pigtail stent placement to manage a case of proximal colo-colonic anastomotic leakage
Authors: Roberto Di Mitri, Ambra Bonaccorso, Filippo Mocciaro, Michele Amata, Elisabetta Conte, Pierenrico Marchesa, Daniela Scimeca
Journal: Endoscopy (2021)

A 39-year-old man underwent a distal spleno-pancreatectomy and colonic resection for a tail pancreatic cancer infiltrating the colonic splenic flexure. Five days after surgery, the patient experienced fever and abdominal pain. A computed tomography (CT) scan showed a 10-cm intra-abdominal collection with free air bubbles inside; oral contrast-medium intake revealed a passage from the colon to the abdominal collection, highly suspicious of an anastomotic leak ([Fig. 1]).
1381P Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): 14-month follow-up of CheckMate 577
Authors: M. Moehler, J.A. Ajani, J. Kuzdzal, T. Zander, E. Van Cutsem, G. Piessen, G. Mendez, J. Feliciano, S. Motoyama, A. Lièvre, H. Uronis, E. Elimova, C. Grootscholten, K. Geboes, J. Zhang, S. Soleymani, M. Lei, K. Kondo, J. Cleary, R.J. Kelly
Journal: Annals of Oncology (2021)
Long-term Outcomes of Transcatheter Arterial Chemoembolization Combined With Radiofrequency Ablation as an Initial Treatment for Early-Stage Hepatocellular Carcinoma
Authors: Yao Jun Zhang, Min Shan Chen, Yong Chen, Wan Yee Lau, Zhenwei Peng
Journal: JAMA Network Open (2021)

<h3>Importance</h3> The long-term outcomes of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) are not determined. <h3>Objective</h3> To report the long-term outcomes of TACE-RFA. <h3>Design, Setting, and Participants</h3> This cohort study analyzed long-term follow-up data from a phase 3 randomized clinical trial of adults with early HCC conducted from October 2006 to June 2009. Participants were randomly assigned to the TACE-RFA group or the RFA group in a 1:1 ratio and followed up approximately 6 years after the trial was closed. Data analysis was performed March 2020. <h3>Exposure</h3> In the TACE-RFA group, TACE was performed first, and RFA was done 2 weeks later. <h3>Main Outcomes and Measures</h3> Overall survival (OS) and recurrence-free survival (RFS). <h3>Results</h3> Of 189 patients who were included (mean [SD] age, 54.3 [12.0] years; 146 [77.2%] men), 94 and 95 patients were assigned to the TACE-RFA group and RFA group, respectively, with their baseline characteristics well matched. Three patients in each group were lost to follow-up. The 5-year and 7-year OS rates for the TACE-RFA group vs the RFA group were 52.0% and 36.4% vs 43.2% and 19.4%, respectively (hazard ratio [HR], 0.55; 95% CI, 0.39-0.78;<i>P</i> = .001). The 5-year and 7-year RFS rates for the TACE-RFA group vs the RFA group were 41.4% and 34.5% vs 27.4% and 18.1%, respectively (HR, 0.66; 95% CI, 0.49-0.89;<i>P</i> = .007). On subgroup analysis comparing patients who had tumors larger than 3 cm with those who had tumors 3 cm or smaller, the OS and RFS survival rates in the TACE-RFA group (HR, 3.20; 95% CI, 1.91-5.35,<i>P</i> &lt; .001) were significantly better than those in the RFA group (HR, 2.03; 95% CI, 1.30-3.17;<i>P</i> = .002). <h3>Conclusions and Relevance</h3> In this cohort study, combined RFA and TACE was associated with better survival than RFA alone on long-term follow-up. Patients with tumors 3 cm or smaller did not benefit as well as patients with tumors larger than 3 cm from the combined treatment.
984P Phase I dose escalation trial of nintedanib in combination with pembrolizumab in patients with advanced solid tumors (PEMBIB trial)
Authors: C. Baldini, F-X. Danlos, A. Varga, H. Halse, S. Mouraud, L. Cassard, D. Bredel, G. Escriou, A. Parpaleix, S. Rafie, A.E. Abbassi, S. Laghouati, S. Farhane, L. Tselikas, M. Texier, J. Adam, N. Chaput, J-C. Soria, C. Massard, A. Marabelle
Journal: Annals of Oncology (2021)
734P Neutrophil-lymphocyte ratio predicts survival in platinum-resistant ovarian cancer patients treated with olaparib and pegylated liposomal doxorubicin (PLD): Stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601
Authors: J.A. Perez Fidalgo, A. Cortés, Y. García, M. Iglesias, U. Bohn Sarmiento, E. Calvo García, L. Manso, A. Santaballa, A. Oaknin, A. Redondo, M.J. Rubio, A. González-Martín
Journal: Annals of Oncology (2021)
Integrating Pediatric Diabetes Education Into Routine Clinical Care
Authors: Helen R. Murphy, Clair Wadham, Gerry Rayman, Chas T. Skinner
Journal: Diabetes Care (2006)

The importance of optimal glycemic control for children and adolescents to prevent the long-term complications of diabetes is well recognized (1). Educational interventions that increase parental involvement in blood glucose monitoring and insulin dose adjustment have demonstrated beneficial effects in specialist centers (2,3). The Families, Adolescents and Children’s Teamwork Study (FACTS) was developed to evaluate a family-centered, structured education program for children and young people that can be integrated into routine clinical care. The small group setting facilitates increased peer group contact for both children and parents and improves cost efficiency, allowing the program to be delivered within existing service …
1752P Characteristics and treatment [tx] patterns in patients [pts] with medullary thyroid cancer [MTC] with and without REarranged during Transfection [RET] mutations in Europe
Authors: A. Rider, L.M. Hess, T. Puri, M-H. Jen, R. Williams, I. Sanderson, U. Kiiskinen
Journal: Annals of Oncology (2021)
Polyphenols and neuroprotection: Therapeutic implications for cognitive decline
Authors: Giuseppe Caruso, Sebastiano A. Torrisi, Maria Paola Mogavero, Walter Currenti, Sabrina Castellano, Justyna Godos, Raffaele Ferri, Fabio Galvano, Gian Marco Leggio, Giuseppe Grosso, Filippo Caraci
Journal: Pharmacology & Therapeutics (2021)
1767P Co-clinical PDX study of trastuzumab deruxtecan in HER2-positive uterine carcinosarcoma (STATICE trial, NCCH1615)
Authors: S. Yagishita, T. Nishikawa, H. Yoshida, D. Shintani, S. Sato, M. Miwa, M. Suzuki, M. Yasuda, K. Yonemori, K. Hasegawa, A. Hamada
Journal: Annals of Oncology (2021)
Abstract 412: Cardiac-Specific Overexpression of Caveolin-3 Induces Endogenous Cardiac Protection
Authors: Hemal H Patel, Yasuo M Tsutsumi, Utako Yokoyama, Paul A Insel, David M Roth
Journal: Circulation (2007)

Caveolae are lipid-rich microdomains of the plasma membrane that localize and enrich cardiac protective signaling molecules. Caveolin-3 (Cav3), the dominant caveolin isoform found in cardiac myocytes, is a determinant of caveolae formation. We hypothesized that cardiac-directed overexpression of Cav3 would enhance the formation of caveolae and augment protective signaling of the heart in vivo . Full-length cDNA for mouse Cav3 was cloned into a vector containing the α-myosin heavy chain promoter to allow for cardiac myocyte-specific expression of Cav3. A transgenic (Tg) mouse line was derived with a 5.5-fold increase in Cav3 mRNA and a 2.4-fold increase in Cav3 protein that localized to the sarcolemma. No significant increase in Cav3 expression was observed in lung, liver, brain, or skeletal muscle from Tg-positive mice. Electron microscopy revealed enhanced formation of caveolae on the sarcolemmal membranes of Tg-positive mice compared to Tg-negative littermate controls and no apparent structural defects in the heart. Echocardiography of 7–9 month old Tg-positive and Tg-negative mice showed no significant differences in cardiac function. Tg-positive mice subjected to ischemia/reperfusion injury had a significantly reduced infarct size relative to Tg-negative mice (23.9 ± 3.3 vs. 44.4 ± 5.9 % risk area, p&lt;0.01). The endogenous protection induced in Cav-3 Tg-positive mice was similar to that produced in wild-type mice undergoing ischemic preconditioning (27.2 ± 2.5 % risk area). Hearts excised from Tg-positive mice had a 1.5-fold increase in basal phosphorylation of Akt (p&lt;0.05, n = 6 Tg positive, 4 Tg-negative). Cardiac protection in Cav3 Tg-positive mice was blocked by treatment prior to ischemia reperfusion with 5-hydroxydecanoate, a mitochondrial KATP channel blocker. These results reveal that cardiac-specific overexpression of Cav3 produces an endogenous protected phenotype in mice in association with greater basal Akt activation and a phenotype that is sensitive to antagonism via mitochondrial KATP channel inhibition. The findings suggest that approaches to increase Cav3 expression may provide a novel means to augment cardiac protection independent of ischemic preconditioning.
1704P Early switch to oral antibiotic therapy in patients with low-risk neutropenic sepsis (EASI-SWITCH trial)
Authors: V. Coyle, C. Forde, R. Adams, R. Barnes, I. Chau, M. Clarke, A. Doran, M. Grayson, D. McAuley, C. McDowell, G. Phair, R. Plummer, A. Thomas, R. Wilson, R. McMullan
Journal: Annals of Oncology (2021)
674P WITNESS: Real-world outcomes of patients (pts) with advanced renal cell carcinoma (aRCC) treated with nivolumab in France and subgroup analysis of patients receiving concomitant medications at baseline
Authors: A. Thiery-Vuillemin, L. Albiges, B. Escudier, B. Narciso, P. Bigot, J-C. Eymard, F. Calcagno, F. Schlürmann, M. Chehimi, J. Barthomeuf, C. Quentric, Y. Vano, P. Barthelemy
Journal: Annals of Oncology (2021)
CN43 Maintaining intravenous anti-cancer systemic therapy during COVID: Pharmacy and nursing factors
Authors: R.T. O'Dwyer, W. Connolly, S. Hamilton, S. Kelly, A. Lynch, F. Martin, K. Dempsey, A. Rondthaler, B. Ryan, A. Byrne, R. Corrigan, R. Lawless, L. Conlon, P. Hickey, A. Manning, K. Egan, O.S. Breathnach, C. O'Shea, A. Christie, L. Treanor
Journal: Annals of Oncology (2021)
Prognostic factors for development of acute respiratory distress syndrome following traumatic injury: a systematic review and meta-analysis
Authors: Alexandre Tran, Shannon M. Fernando, Laurent J. Brochard, Eddy Fan, Kenji Inaba, Niall D. Ferguson, Carolyn S. Calfee, Karen E.A. Burns, Daniel Brodie, Victoria A. McCredie, Dennis Y. Kim, Kwadwo Kyeremanteng, Jacinthe Lampron, Arthur S. Slutsky, Alain Combes, Bram Rochwerg
Journal: European Respiratory Journal (2021)

Background Our purpose was to summarise the prognostic associations between various clinical risk factors and development of acute respiratory distress syndrome (ARDS) following traumatic injury. Methods We conducted this review in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) and CHARMS (Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies) guidelines. We searched six databases from inception through December 2020. We included English language studies describing the clinical risk factors associated with development of post-traumatic ARDS, as defined by either the American–European Consensus Conference or Berlin definition. We pooled adjusted odds ratios for prognostic factors using the random effects method. We assessed risk of bias using the QUIPS (Quality in Prognosis Studies) tool and certainty of findings using GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology. Results We included 39 studies involving 5 350 927 patients. We identified the amount of crystalloid resuscitation as a potentially modifiable prognostic factor associated with development of post-traumatic ARDS (adjusted OR 1.19, 95% CI 1.15–1.24 for each additional litre of crystalloid administered within the first 6 h after injury; high certainty). Non-modifiable prognostic factors with a moderate or high certainty of association with post-traumatic ARDS included increasing age, non-Hispanic White race, blunt mechanism of injury, presence of head injury, pulmonary contusion or rib fracture and increasing chest injury severity. Conclusions We identified one important modifiable factor, the amount of crystalloid resuscitation within the first 24 h of injury, and several non-modifiable factors associated with development of post-traumatic ARDS. This information should support the judicious use of crystalloid resuscitation in trauma patients and may inform development of risk stratification tools.
495P Clinical characteristics, prognostic factors and survival of early-onset colorectal cancer (EOCRC) in a Spanish cohort
Authors: J. Soto Alsar, N. Gutiérrez Alonso, M. Bringas Beranek, C. López Jiménez, A. Gutiérrez Ortiz de la Tabla, M. Alva Bianchi, R. Jiménez Rodríguez, R. Martín Lozano, L. Ortega Morán, G. Torres Pérez-Solero, A. Muñoz Martín, A. Calvo, M. Blanco, M. Arregui Valles, M.I. Aparicio Salcedo, M. Martin, P. García-Alfonso
Journal: Annals of Oncology (2021)
1357P A deep radiomics approach to assess PD-L1 expression and clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: A multicentric study
Authors: M. Tonneau, K. Phan, S. Kazandjian, A. Elkrief, J. Panasci, C. Richard, A. Nolin-Lapalme, R. El Sayed, L. Ding, T. Nair, J. Malo, F. Chandelier, K. Kafi, J. O'Brien, L. Di Jorio, T. Muanza, B. Routy
Journal: Annals of Oncology (2021)
1821P Safety and preliminary efficacy of vimseltinib in tenosynovial giant cell tumor (TGCT)
Authors: H. Gelderblom, A.R. Abdul Razak, A. Sánchez-Gastaldo, P. Rutkowski, B. Wilky, A. Wagner, M. van de Sande, M. Michenzie, M. Vallee, M. Sharma, M.L. Sherman, R. Ruiz-Soto, W. Tap
Journal: Annals of Oncology (2021)
Hematologic complications of immune checkpoint inhibitors
Authors: Michael H. Kroll, Cristhiam Rojas-Hernandez, Cassian Yee
Journal: Blood (2021)

Immune checkpoint inhibitors are a class of antineoplastic therapies that unleash immune cells to kill malignant cells. There are currently 7 medications that have been approved by the US Food and Drug Administration for the treatment of 14 solid tumors and 2 hematologic malignancies. These medications commonly cause immune-related adverse effects as a result of overactive T lymphocytes, autoantibody production, and/or cytokine dysregulation. Hematologic toxicities are rare and of uncertain mechanism, and therefore management is often based on experiences with familiar conditions involving these perturbed immune responses, such as autoimmune hemolytic anemia, immune thrombocytopenia, and idiopathic aplastic anemia. Management is challenging because one must attend to the hematologic toxicity while simultaneously attending to the malignancy, with the imperative that effective cancer therapy be maintained or minimally interrupted if possible. The purpose of this review is to help clinicians by providing a clinical and pathophysiological framework in which to view these problems.
Oncolytic cancer therapy using lipofectamine-conjugated herpes simplex virus for the reduction of viral antigenicity
Authors: Tomohiro Deguchi, Hideki Kasuya
Journal: Cancer Research (2005)

3367  Herpes simplex virus (HSV) vectors are used in many type of cancer gene therapy trial. HSV has an efficacy of tumor selective cytotoxity against cancer cells with its oncolytic mechanism. But the efficacy of Viruses is limited by immune response that reduced transgene expression and decreased the efficacy of repeated vector administration. We demonstrated that lipofectamine-conjugated HSV reduced viral antigenicity in vivo, and showed higher transfection efficacy in vitro than virus alone. In the group of mice bearing metastatic liver tumor of mouse colon cancer (MC26), there was a tendency that mice injected with lipofectamine-conjugated HSV was survived for long term more than virus alone. (There was no statistic difference.) Several reports showed cationic lipid or molecules could bind to adenovirus and increase the efficacy of gene transfer to a variety of cells. In the electron microscopy, we found that lipofectamine stood close to cell surface membrane and many viruses could be seen inside of membrane of lipofectamine in the contrast with that only a few virus has been seen on the cell surface in the group of virus alone. We considered the lipofectamine helped viral transfection to cells. And we checked the viral antigenicity. In the evaluation of IgG in the blood of group of mice with lipofectamine-conjugated HSV showed less value than with viruses only. That means less immunogenic caused by the effect of lipofectamine. Hence, the lipofectamine reduced viral antigenicity, repeated administration could be allowed to attempt safer than virus alone. In the evaluation of IgM and IgE, there was no big difference between conjugated with or without. And, we injected lipofectamine-conjugated HSV or virus alone into the spleen of mice bearing metastatic liver tumor of MC26. Then DNA was extracted from liver and lung tissues of them. We found that virus’s DNA existed definitely more in the metastatic liver of MC26 than in the lung by PCR assay. This evidence was obviously seen in the group of mice treated by the injection of lipofectamine conjugated HSV. That means lipofectamine conjugated virus might be safer and more effective than virus alone.
1602P COVID-19 vaccination efficacy in cancer patients: An ongoing prospective trial
Authors: T.F. Da Cruz Tomas, I.F. Eiriz, M. Vitorino, R.S. Vicente, A.D. Mendes, M.C. Silva Sousa, S. Braga, T.M. Fiuza, L.A. Gonçalves, C.P. Gonçalves, J. Demengeot
Journal: Annals of Oncology (2021)